Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology

Annals of the Rheumatic Diseases

Volumn 74, Issue 6, 2015, Pages 963-969

  Buch, Maya H ^a,b   Silva Fernandez, Lucia ^c   Carmona, Loreto ^d   Aletaha, Daniel ^e   Christensen, Robin ^f   Combe, Bernard ^g   Emery, Paul ^a,b   Ferraccioli, Gianfranco ^h   Guillemin, Francis ⁱ   Kvien, Tore K ^j   Landewe, Robert ^k   Pavelka, Karel ^l   Saag, Kenneth ^m   Smolen, Josef S ^e,n   Symmons, Deborah ^o,p   Van Der Heijde, Désirée ^q   Welling, Joep ^r   Wells, George ^s   Westhovens, Rene ^t,u   Zink, Angela ^v   Boers, Maarten ^w   more..

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^c HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^d Institute for Health   (Spain)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f FREDERIKSBERG HOSPITAL   (Denmark)

^g LAPEYRONIE HOSPITAL   (France)

^h CATHOLIC UNIVERSITY   (Italy)

ⁱ UNIVERSITÉ DE LORRAINE   (France)

^j DIAKONHJEMMET HOSPITAL   (Norway)

^k UNIVERSITY OF AMSTERDAM   (Netherlands)

^l CHARLES UNIVERSITY   (Czech Republic)

^m University of Alabama at Birmingham   (United States)

ⁿ Hietzing Hospital   (Austria)

^o UNIVERSITY OF MANCHESTER   (United Kingdom)

^p MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^q LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^r EULAR Patient Research Partner   (Netherlands)

^s UNIVERSITY OF OTTAWA   (Canada)

^t SKELETAL BIOLOGY AND ENGINEERING RESEARCH CENTER   (Belgium)

^u UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^v German Rheumatism Research Centre   (Germany)

^w VU UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PRACTICE; CLINICAL STUDY; DELPHI STUDY; HEALTH CARE MANAGEMENT; HUMAN; MEDICAL ETHICS; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PRIORITY JOURNAL; RHEUMATOLOGY; STANDARDIZATION; TOTAL QUALITY MANAGEMENT; TRIAL EXTENSION STUDY; ADVISORY COMMITTEE; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH; STANDARDS;

ADVISORY COMMITTEES; DELPHI TECHNIQUE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RESEARCH REPORT; RHEUMATOLOGY;

EID: 84934983813     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204948     Document Type: Article

References (29)

1. O'Dell JR, Leff R, Paulsen G, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1164-70.
2. Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
3. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
4. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
5. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
6. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.
7. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-23.
8. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.
9. Smolen J, Landewe RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009;68:797-804.
10. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009;68:789-96.
11. Nuki G, Bresnihan B, Bear MB, et al. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:2838-46.
12. Nishimoto N, Miyasaka N, Yamamoto K, et al. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009;68:1580-4.
13. Keystone E, Fleischmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007;56:3896-908.
14. Genovese MC, Bathon JM, Fleischmann RM, et al. Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol 2005;32:1232-42.
15. Westhovens R, Kremer JM, Moreland LW, et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol 2009;36:736-42.
16. Scott DL, Smolen JS, Kalden JR, et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001;60:913-23.
17. Wollenhaupt J, Silverfeld J, Bong Lee E, et al. Tofacitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: open-label, long-term extension safety and efficacy up to 5 years. Arthritis Rheum 2013;65(S2328).
18. Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401-6.
19. Buch MH, Aletaha D, Emery P, et al. Reporting of long-term extension studies: lack of consistency calls for consensus. Ann Rheum Dis 2011;70:886-90.
20. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg 2012;10:28-55.
21. Aletaha D, Landewe R, Karonitsch T, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis 2008;67:1360-4.
22. Dixon WG, Carmona L, Finckh A, et al. EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. Ann Rheum Dis 2010;69:1596-602.
23. Christensen R, Bliddal H, Henriksen M. Enhancing the reporting and transparency of rheumatology research: a guide to reporting guidelines. Arthritis Res Ther 2013;15:109.
24. Dougados M, Betteridge N, Burmester GR, et al. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis 2004;63:1172-6.
25. Vandenbroucke JP. STREGA, STROBE, STARD, SQUIRE, MOOSE, PRISMA, GNOSIS, TREND, ORION, COREQ, QUOROM, REMARK... and CONSORT: for whom does the guideline toll? J Clin Epidemiol 2009;62:594-6.
26. Jones J, Hunter D. Consensus methods for medical and health services research. BMJ 1995;311:376-80.
27. Kristensen LE, Saxne T, Geborek P. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum 2006;54:600-6.
28. Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ 2008;337:a2390.
29. von Elm E, Altman DG, Egger M, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007;335:806-8.